And the numbers continue to rise
However, how your body responds to this dose depends on multiple factors: genetic variants in GIPR pathways, baseline metabolic markers, body composition, and individual pharmacokinetics
Hellstrom PM, Hein J, Bytzer P, Bjornsson E, Kristensen J, Schambye H (2009) Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study
If your prescriber recommends combining sermorelin with tirzepatide, ask three questions: what IGF-1 target are we aiming for, how will we assess lean mass preservation objectively (DEXA scan, not scale weight), and what's the planned duration before reassessing whether both peptides are still necessary